Association Between Non-alcoholic Fatty Liver Disease and Iron Status
NCT ID: NCT01307254
Last Updated: 2012-09-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
80 participants
OBSERVATIONAL
2011-01-31
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of the study is to show the association between the severity of Non-alcoholic fatty liver disease to low iron status.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a preliminary study that will aid in planning future strategies to treat or even prevent fatty liver (one of the epidemics of our century).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Non alcoholic fatty liver disease
blood analysis
A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)
control
blood analysis
A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood analysis
A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI\>25
Exclusion Criteria
* unable to sign an informed consent (legally)
* known solid/hematological malignancy
* hemoglobinopathy or myelodysplastic disease (not including G6PD deficiency)
* active or carrier of viral hepatitis
* treated a drug the cause fatty liver (eg. amiodarone, tetracyclin, HAART, steroid treatment \> 3 months)
* consumption of \> 120g ethanol per week
* primary liver disease (eg. glycogen storage disease)
* CRP\>20
* acute intoxication
* surgery in previous 7 days
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Prof Doron Zamir
UNKNOWN
Ornit Cohen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ornit Cohen
r&d unit
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Barzilai medical center
Ashkelon, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Albert Grinshpun
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BAFLA
Identifier Type: -
Identifier Source: org_study_id